otiloniumbromid

Otilonium bromide is a prescription antispasmodic used to treat irritable bowel syndrome (IBS) and other functional bowel disorders. It is a quaternary ammonium compound designed to act locally in the gastrointestinal tract with limited systemic absorption, which helps minimize systemic anticholinergic effects.

Mechanism of action: The drug reduces intestinal smooth muscle contractions by a combination of calcium channel blockade and antagonism of muscarinic receptors on smooth muscle and enteric nerves. This spasmolytic action can decrease abdominal pain, cramps, and bloating associated with IBS. Some sources note effects on neural signaling in the gut, contributing to symptom relief.

Pharmacokinetics: Following oral administration, most of the drug remains in the GI tract due to limited absorption. The small amount that is absorbed is metabolized and cleared, with excretion via urine and feces. The formulation and dosing may vary by country.

Clinical use: Otilonium bromide is used to alleviate cramping, pain, and bloating in IBS and other functional bowel disorders. It is typically prescribed as part of a symptomatic management plan and is not intended to cure the underlying condition.

Safety and adverse effects: Because of its poor systemic absorption, systemic anticholinergic effects are uncommon, but mild dry mouth, constipation, or blurred vision can occur in some patients. Severe adverse reactions are rare. Cautions include use in glaucoma, urinary retention, or intestinal obstruction and avoidance in hypersensitive individuals. Interactions with other anticholinergic drugs or certain medications should be considered.

Regulatory status: Otilonium bromide is approved and marketed in several European and other markets; availability varies by country. It may be sold under multiple brand names.